<unk>  (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in patients with metastasizing cancer. It binds to antigens CD3 and EpCAM. It is in clinical trials in the United States currently and is used in Europe. It was developed by Fresenius Biotech and Trion Pharma (Germany).
Catumaxomab
Arcitumomab
Tildrakizumab
Risankizumab
Abagovomab
Blinatumomab
Mogamulizumab
Idarucizumab